📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-07 19:30
122 analysed today
FollowTelegram
122
Today
149,523
All-time analysed
42,890
Positive
6,652
Negative
91,308
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
9 announcements match the current filters (relevance ≥ 5).
47% Y-o-Y Revenue Growth for HealthX as Gross Margins Expand to 7.9%
HealthX Platform Limited (formerly Sastasundar Ventures) reported a strong 47% Y-o-Y revenue growth for the June 2026 quarter, with top-line momentum across all channels. Gross margins improved by 130 bps Y-o-Y to 7.9%, driven by better sourcing and a higher private-label mix. The company has successfully transitioned back to 100% ownership of the SastaSundar platform following the exit of Flipkart Health+ as an associate in FY25. While the company remains near break-even with an FY26 PAT of Rs -1.4 cr, it maintains a lean working capital cycle of 28 days.
Confidence: HIGH
What changedThe company has moved from a 25% minority stake in its core platform back to 100% ownership and is reporting accelerated growth post-restructuring.
Why it mattersRegaining full control allows HealthX to execute its AI-powered digital health strategy without external partner constraints, though it must now fund its own scaling and infrastructure.
Revenue (Q1 FY27): Rs 459.7 crY-o-Y Revenue Growth: 47%Gross Margin (June-26): 7.9%Working Capital Days: 28 daysRetailer Shakti CAGR: 96%
📅 Short termThe strong quarterly growth and margin expansion are likely to be viewed positively by the market in the coming weeks.
📈 Long termThe structural shift to 100% ownership and an asset-light model provides a long-term runway for scaling, provided the company can achieve sustainable PAT margins.
⚠ Risk flags
- Historical volatility in growth during partnership transitions
- Current near-break-even profitability
- High competition in the digital pharmacy and healthcare distribution space
Key Highlights
Revenue grew 47% Y-o-Y and 16% Q-o-Q for the quarter ended June 2026.
Gross Margin expanded by 130 bps Y-o-Y to reach 7.9% in the current quarter.
Retailer Shakti platform achieved a 96% CAGR from FY20 to FY26, with sales reaching Rs 1,125 cr.
Net working capital cycle improved to 28 days, representing an 11% Y-o-Y reduction.
The company regained 100% operational control of SastaSundar after the Flipkart partnership ended in FY25.
👀 What to Watch
Investors should monitor the company's ability to convert high top-line growth into bottom-line profitability now that it has full operational control. Key metrics to watch include the continued expansion of gross margins and the absorption of fixed costs through operating leverage.
Health X Platform Reports Q1 Net Loss of ₹51.43 Lakhs; Revenue Declines 17% YoY
Health X Platform Limited (formerly Sastasundar Ventures) reported a standalone net loss of ₹51.43 lakhs for the quarter ended June 30, 2026, compared to a loss of ₹10.95 lakhs in the same period last year. Revenue from operations fell to ₹8.00 lakhs from ₹9.67 lakhs YoY, while total expenses surged to ₹60.72 lakhs. The company is currently undergoing a composite scheme of arrangement and amalgamation with Microsec Resources Private Limited, which is pending regulatory approval. Additionally, the board approved the re-appointment of Mrs. Anjana Dikshit as an Independent Director for a second five-year term.
Confidence: HIGH
What changedThe company reported a widening quarterly loss and confirmed the re-appointment of an Independent Director while providing an update on its pending corporate restructuring.
Why it mattersThe widening losses and low revenue base indicate significant operational stress; the pending merger/demerger scheme is the key structural event that could redefine the company's business model.
Revenue from Operations (Q1): ₹8.00 LakhsNet Loss (Q1): ₹51.43 LakhsTotal Expenses (Q1): ₹60.72 LakhsOther Expenses (Q1): ₹50.30 LakhsIndependent Director Term: 5 years
📅 Short termThe stock may face downward pressure due to the widening losses and weak operational revenue reported for the June quarter.
📈 Long termThe long-term trajectory depends on the successful execution of the restructuring scheme and the ability of the healthcare segment to achieve operational break-even.
⚠ Risk flags
- Operational losses in step-down subsidiary Genu Path Labs Limited
- Significant widening of standalone net loss
- High 'Other Expenses' relative to total revenue
Key Highlights
Standalone net loss widened significantly to ₹51.43 lakhs in Q1 FY27 from ₹10.95 lakhs in Q1 FY26.
Revenue from operations decreased by 17.3% YoY to ₹8.00 lakhs.
Total expenses increased to ₹60.72 lakhs, primarily driven by 'Other Expenses' amounting to ₹50.30 lakhs.
Re-appointment of Mrs. Anjana Dikshit as Independent Director for a 5-year term starting November 10, 2026.
A composite scheme of arrangement with Microsec Resources Private Limited is pending, with an appointed date of April 01, 2026.
👀 What to Watch
Investors should monitor the regulatory approval timeline for the 'Composite Scheme of Arrangement' and the operational performance of the 'Healthcare Network' segment, which has been facing losses.
Health X Platform FY26 Revenue Grows 18% to ₹1,283 Cr; Annual PAT Loss Nears Break-even
Health X Platform Limited (formerly Sastasundar Ventures) reported a strong operational turnaround in FY26, with revenue reaching ₹1,283 crore, up 18% YoY. The company significantly narrowed its annual PAT loss to ₹1.4 crore from ₹133 crore in FY25, driven by improved gross margins of 7.5% and better procurement efficiency. Management highlighted an industry-leading working capital cycle of 18 days and a long-term revenue target of ₹6,000 crore by FY2030. Additionally, a corporate restructuring is underway to demerge the Finance Division into a separate listed entity, Microsec Resources Ltd.
Key Highlights
FY26 revenue increased 18% YoY to ₹1,283 crore, while Q4 FY26 revenue grew 22% to ₹356 crore.
Annual PAT loss reduced drastically to ₹1.4 crore in FY26 compared to a loss of ₹133 crore in the previous year.
Maintained high capital efficiency with a working capital cycle of 18 days, representing only 5% of annual sales.
Launched 'JITO' genetic medicine category, achieving initial sales of ₹30 lakhs per month with prices up to 60% lower than branded alternatives.
Board approved a 1:3 demerger ratio for the Finance Division into Microsec Resources Ltd to simplify corporate structure.
👀 What to Watch
Investors should view the narrowing losses and high capital efficiency as strong indicators of a maturing business model. Monitor the execution of the ₹6,000 crore FY30 revenue target and the upcoming demerger of the finance wing for potential value unlocking.
Health X to Demerge Finance Business into MRL; 1:3 Share Swap and Listing Planned
Health X Platform Limited has announced a composite scheme to simplify its corporate structure by separating its healthcare and financial services businesses. The financial business will be demerged into Microsec Resources Private Limited (MRL), with shareholders receiving 1 share of MRL for every 3 shares held in Health X. Additionally, Sastasundar Healthbuddy Limited will merge into Health X, increasing the public shareholding in Health X from 25.93% to 41.57%. The scheme aims to unlock value and provide operational independence for both segments, with MRL slated for listing on BSE and NSE.
Key Highlights
Demerger of finance business into MRL with a 1:3 share swap ratio for Health X shareholders.
MRL to be converted to a public company and listed on BSE and NSE for liquidity.
Merger of SHBL into Health X, resulting in the issuance of 85,12,168 new shares to SHBL public holders.
Health X public shareholding to significantly expand from 25.93% to 41.57% post-scheme.
Expected implementation timeline of 12-14 months, targeting completion by July 2027.
👀 What to Watch
Investors should maintain their positions to benefit from the value unlocking of the financial services business and the consolidation of the healthcare segment. Monitor the NCLT and regulatory approval process over the next year for any timeline shifts.
Health X Platform Announces Restructuring: 1:3 Demerger Ratio and Merger of Healthbuddy Unit
Health X Platform Limited (formerly Sastasundar Ventures) has approved a composite scheme of arrangement to separate its financial and healthcare businesses. The financial services division, which contributed 1.10% (₹1,519.05 lakhs) to consolidated turnover in FY26, will be demerged into Microsec Resources Private Limited, with shareholders receiving 1 share for every 3 shares held in Health X. Additionally, the company will merge its subsidiary Sastasundar Healthbuddy Limited into itself to consolidate healthcare operations, issuing 85.12 lakh shares to minority holders. The appointed date for this restructuring is April 1, 2026.
Key Highlights
Demerger ratio set at 1 equity share of Microsec Resources for every 3 equity shares held in Health X Platform.
Amalgamation of Sastasundar Healthbuddy into Health X involves issuing 85,12,168 new shares for 45,75,830 shares held by non-promoters.
The demerged financial services undertaking reported a turnover of ₹1,519.05 lakhs against a consolidated total of ₹1,37,753.67 lakhs in FY26.
Health X Platform (Consolidated) reported total assets of ₹93,576.87 lakhs as of March 31, 2026.
The scheme aims to unlock value by creating a focused entity for financial services and streamlining the healthcare supply chain.
👀 What to Watch
Investors should maintain their positions to benefit from the value unlocking of the separate financial services entity and the simplified corporate structure of the core healthcare business. Monitor the NCLT approval process and the record date for the share entitlement.
Health X Platform Approves Major Restructuring; 1:3 Demerger Ratio for Financial Services
Health X Platform Limited (HEALTHX) has approved a composite scheme of arrangement involving a demerger and multiple amalgamations. The company will demerge its financial services division into Microsec Resources Private Limited, with shareholders receiving 1 share of the new entity for every 3 shares held in HEALTHX. Simultaneously, Sastasundar Healthbuddy Limited (SHBL) will merge into HEALTHX, consolidating the healthcare business. The demerged financial division contributed 1.10% (₹1,519.05 lakhs) to the total consolidated turnover of ₹1,37,753.67 lakhs in FY26.
Key Highlights
Shareholders to receive 1 share of Microsec Resources for every 3 shares held in Health X Platform.
Health X to issue 85,12,168 equity shares to minority shareholders of Sastasundar Healthbuddy Limited (SHBL) for its merger.
The demerged financial services undertaking reported a turnover of ₹1,519.05 lakhs, representing 1.10% of consolidated revenue.
Consolidated assets of Health X Platform stood at ₹93,576.87 lakhs as of March 31, 2026.
The appointed date for the scheme is April 1, 2026, subject to NCLT, RBI, and SEBI approvals.
👀 What to Watch
Investors should maintain their positions to benefit from the potential value unlocking of the financial services business and a more focused healthcare entity. Monitor the timeline for NCLT approvals and the eventual listing of the demerged entity.
Health X Platform FY26 Revenue Grows 20% to ₹1,306 Cr; Net Loss Narrows to ₹1.4 Cr
Health X Platform Limited (formerly Sastasundar Ventures) reported a 20% YoY revenue growth to ₹1,305.9 crore for FY26, driven by its B2B 'Retailer Shakti' platform. The company significantly narrowed its consolidated net loss to ₹1.4 crore in FY26 from a loss of ₹133.5 crore in FY25. Operational efficiency improved as working capital days decreased by 31% YoY to 18 days. The company is aggressively expanding its fulfillment capacity from 2.21 lakh sq. ft. to over 7.26 lakh sq. ft. with new centers in Lucknow, Udaipur, and Patna.
Key Highlights
FY26 Revenue from operations increased 20% YoY to ₹1,305.9 crore compared to ₹1,088.1 crore in FY25.
Consolidated net loss significantly reduced to ₹1.4 crore in FY26 from ₹133.5 crore in the previous fiscal year.
Working capital cycle improved by 31% YoY, dropping from 23 days to 18 days as of March 2026.
Gross Profit margin improved to 7.5% in FY26 from 6.5% in FY25, with Q4 FY26 margins reaching 7.3%.
Planned expansion of fulfillment capacity by 5.05 lakh sq. ft. to target Northern and Eastern Indian markets.
👀 What to Watch
Investors should note the company's significant progress toward profitability and improved capital efficiency. Monitor the successful commissioning of new fulfillment centers as a key driver for the next phase of growth.
Health X Platform Reports FY26 Audited Results with Unmodified Auditor Opinion
Health X Platform Limited (formerly Sastasundar Ventures Limited) has approved its audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The statutory auditor, JKVS & Co, issued an unmodified opinion, though the report confirms the company recorded a net loss and other comprehensive loss for the period. Additionally, the board has re-appointed M/s. Priya Gupta & Co. as the internal auditor for the 2026-27 financial year to oversee internal controls.
Key Highlights
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Statutory auditors JKVS & Co provided an unmodified audit opinion, ensuring financial transparency.
The company reported a net loss and other comprehensive loss for the full financial year 2025-26.
Re-appointed M/s. Priya Gupta & Co. as Internal Auditor for the upcoming FY 2026-27.
The board meeting concluded at 5:30 P.M. on May 30, 2026, following a 3:00 P.M. start.
👀 What to Watch
Investors should examine the full financial statements to determine the magnitude of the net loss and identify if there are signs of operational recovery. Monitor the company's performance under its rebranded identity for any strategic shifts in the health platform sector.
Health X Platform Subsidiary Stake Sale: Mitsubishi Exits 4.68% Stake to Envision India Fund
Health X Platform Limited has announced the completion of a stake transfer in its material subsidiary, Sastasundar Healthbuddy Limited. Mitsubishi Corporation has exited its entire 4.68% stake, comprising 10,13,766 equity shares, which have been acquired by Envision India Fund. The transaction, originally initiated in February 2026, was finalized on May 12, 2026. This move marks a change in the institutional shareholding structure of the company's core subsidiary.
Key Highlights
Mitsubishi Corporation sold its entire 4.68% stake in Sastasundar Healthbuddy Limited
A total of 10,13,766 equity shares were transferred to Envision India Fund
The transaction was completed on May 12, 2026, following a Share Purchase Agreement from February 2026
Mitsubishi Corporation has officially ceased to be a shareholder in the material subsidiary
👀 What to Watch
Investors should monitor if the entry of Envision India Fund brings any strategic changes to the subsidiary's operations. The transaction is a secondary stake sale and does not directly impact the parent company's cash flow or ownership.
